Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;44(3):363-365.
doi: 10.1097/FTD.0000000000000972.

What Is the Therapeutic Reference Range for Levetiracetam? Grand Round/A Case Study

Sylvain Couderc  1 , Mondher Chouchane  2 , Franck Saint-Marcoux  1
Affiliations

What Is the Therapeutic Reference Range for Levetiracetam? Grand Round/A Case Study

Sylvain Couderc et al. Ther Drug Monit. .

Abstract

The Therapeutic Drug Monitoring guidelines of Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie had proposed a therapeutic reference range of 10-40 mg/L for levetiracetam in 2011. In the first version of the 2017 update, it was changed to 20-40 mg/L; however, 5 months later, in an erratum version, it was changed back to 10-40 mg/L. In this study, the authors agree with the range to 10-40 mg/L but discuss to what extent a wider interval may be proposed for certain patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195–235.
    1. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
    1. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51:e1.
    1. Stepanova D, Beran RG. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). Seizure. 2014;23:371–376.
    1. Leppik IE, Rarick JO, Walczak TS, et al. Effective levetiracetam doses and serum concentrations: age effects. Epilepsia. 2002;43(suppl 7):240.

LinkOut - more resources